Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Clinical trial NCT04506086 · TERMINATED
Trial details
- NCT number
- NCT04506086
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-26
- Primary completion
- 2024-07-04
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.